Citigroup’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Citigroup’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,532	Closed	-$350K	–	7941
2019 Q3	$350K	Sell	12,532 -50,176	-80%	-$813K	﹤0.01%	4669
2019 Q2	$884K	Buy	62,708 +456	+0.7%	+$4.34K	﹤0.01%	3783
2019 Q1	$553K	Sell	62,252 -5,315	-8%	-$43.1K	﹤0.01%	4078
2018 Q4	$512K	Buy	67,567 +91	+0.1%	+$1.47K	﹤0.01%	4104
2018 Q3	$1.42M	Buy	67,476 +1,604	+2%	+$38.2K	﹤0.01%	3103
2018 Q2	$1.97M	Sell	65,872 -96	-0.1%	-$2.61K	﹤0.01%	2690
2018 Q1	$1.79M	Buy	65,968 +64,540	+4,520%	+$1.93M	﹤0.01%	2696
2017 Q4	$41K	Buy	+1,428	New	+$39.1K	﹤0.01%	6318

Citigroup's DOVA Position: Q4 2019 in Review

Citigroup sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 12,532 shares — an estimated $350K sold.

Citigroup first reported a position in DOVA in Q4 2017 and held it in 8 quarters. The position peaked at $1.97M in Q2 2018. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

Citigroup reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Citigroup sold 12,532 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $350K.
Citigroup first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
Citigroup's Dova Pharmaceuticals, Inc. Common Stock position peaked at $1.97M in Q2 2018.
0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.